ADMA Biologics Completes Acquisition of Biotest Pharmaceuticals Corp (BPC) Therapy Business Unit Assets.

See the Press Release

Groundbreaking Immunotechnology,
One Connection at a Time.

Superior Solutions Come From Superior Commitment

ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us, and our hands-on approach to production and development that sets us apart.

Why does it matter? Because patients are counting on us.

Pipeline of Proprietary Solutions

RI-002, our lead product candidate, is derived from tailored immune globulin pools and targets the unmet needs of immunodeficient patients. Through our proprietary immunotechnology platform, donors with high-titer antibodies were screened and identified. RI-002 demonstrated positive Phase III results, successfully meeting its primary end point of preventing serious bacterial infections such as bacterial pneumonia, osteomyelitis, and bacterial sepsis in immunocompromised patients with Primary Immunodeficiency Diseases (PIDD). The majority of patients in this study did not experience any infusion-related AEs or complications. There were no SAEs reported during the trial attributable to the study drug. There was a low incidence of adverse infusion reactions, with a total of 31 events experienced by 18 patients.